IndraLab
Statements
sparser
"PubMed, EMBASE® and the Cochrane Central Register of Controlled Trials (CCTR) were systematically reviewed for research articles pertaining to known CYP mediated CAM-drug interactions; case reports describing adverse events in patients, and clinical trials which examined the effects of herbs and supplements used during cancer treatment."
sparser
"Table II Inter-residue S···C/N interaction*
Protein
Cysteine
Partner
Name
PDB code Residue Structure Atom Residue Structure
(A) Main-chain partner
Hemoglobin
lBAB 105(A) H(9117) N M33
H(l2115)
Ferredoxin Glycogen phosphorylase B Cytochrome P450-CAM
lFDD lGPB 1PHB
11 495 85
T T
s
N D95
c W491 c G93
T I H(4/6)
148 E(2/3) N F150
H(1/4)
Cyclophilin A Myohemerythrin Glutathione reductase
Aconitase
2CPL 2MHR 3GRS
8ACN
161 35 333 440 178 257
E(6/8) N
H(l7119) c G(4/4) c
H(l/13) E(2/4) H(8110)
N
c c c
K49 N43 A328 G437 Gl71 Gl72 S268
T H(3/24) E(3/3)
s
G(417) G(517)
E(2/3)
Lactate dehydrogenase
9LDT
187(A) E(l/2) N Gl77(A) H(l2/15)
cc~ T306(B)
(B) Side-chain partner Cytochrome P450-CAM
1PHB 85
s
NE2 Q317
E(l/3)
Tyrosine kinase transforming protein 1SHA 42
E(2/9) NH2 R32
E(4/5)
Bovine papilloma virus <::ytochrome P450
2BOP 2HPD
327 62
E(l/7) NE R386 T CG N395
H(4110)
s
*Atom labels, according to the PDB convention, are given."